The Metastatic Prostate Cancer drugs in development market research report provides comprehensive information on the therapeutics under development for Metastatic Prostate Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Metastatic Prostate Cancer. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Metastatic Prostate Cancer and features dormant and discontinued products.
GlobalData tracks 75 drugs in development for Metastatic Prostate Cancer by 70 companies/universities/institutes. The top development phase for Metastatic Prostate Cancer is phase i with 28 drugs in that stage. The Metastatic Prostate Cancer pipeline has 68 drugs in development by companies and seven by universities/ institutes. Some of the companies in the Metastatic Prostate Cancer pipeline products market are: Advanced Accelerator Applications, Bristol-Myers Squibb and Luye Pharma Group.
The key targets in the Metastatic Prostate Cancer pipeline products market include Gonadotropin Releasing Hormone Receptor, Glutamate Carboxypeptidase 2, and DNA.
The key mechanisms of action in the Metastatic Prostate Cancer pipeline product include Gonadotropin Releasing Hormone Receptor Agonist with five drugs in Pre-Registration. The Metastatic Prostate Cancer pipeline products include 14 routes of administration with the top ROA being Intravenous and 14 key molecule types in the Metastatic Prostate Cancer pipeline products market including Small Molecule, and Monoclonal Antibody.
Metastatic Prostate Cancer overview
Metastatic prostate cancer occurs when cancerous cells from the prostate gland spread via the bloodstream or lymphatic system to distant sites, especially the bones (such as the spine, pelvis, or hips), lymph nodes, liver, lungs, and other organs. It’s considered an advanced stage of prostate cancer and can present challenges in treatment and management. Metastatic prostate cancer can cause various symptoms depending on the organs affected, including bone pain (often in the spine, hips, or ribs), urinary problems, erectile dysfunction, weakness or numbness in the legs or feet, weight loss, and fatigue.
For a complete picture of Metastatic Prostate Cancer’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
